ArticleAdvanced materials (Deerfield Beach, Fla.)2024
Rapid Generation of hPSC-Derived High Endothelial Venule Organoids with In Vivo Ectopic Lymphoid Tissue Capabilities.
Article in Advanced materials (Deerfield Beach, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Intratumoral high endothelial venules in solid tumors: a pooled study.Frontiers in immunology · 2024Pooled it
- Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix.Bioactive materials · 2026Article
- Engineering Lymphatic Vessels and Lymphoid Microenvironments In Vitro to Investigate Immune Cell Trafficking.Current opinion in biomedical engineering · 2026Article
- Biomimetic delivery of a STING agonistMaterials today. Bio · 2026Article
- The formation and function of tertiary lymphoid structures.Biomarker research · 2026Review
- T Cell Exhaustion and Dendritic Cell-Mediated Tertiary Lymphoid Structures (TLSs) Modulation Affect Response to Neoadjuvant Chemoradiotherapy in Microsatellite Stable Rectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.Frontiers in immunology · 2026Review
- From TLS architecture to functional immune niches: division of labor among CAFs, HEVs, and antigen-presenting cells in cancer immunotherapy.Frontiers in immunology · 2026Review
- Rebuilding the MarrowOnco · 2025Article
- Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- From Lymphotoxin to Tertiary Lymphoid Structures and Beyond.Immunological reviews · 2025Review
- Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma.Clinical and translational medicine · 2025Review
- Immune organoid for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- The Sunrise of Tertiary Lymphoid Structures in Cancer.Immunological reviews · 2025Review
- Organoids in Haematologic Research: Advances and Future Directions.Cell proliferation · 2025Review
- Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer.Journal of translational medicine · 2025Article
- Organoids as Sophisticated Tools for Renal Cancer Research: Extensive Applications and Promising Prospects.Cellular and molecular bioengineering · 2024Review
- A streamlined method to generate endothelial cells from human pluripotent stem cells via transient doxycycline-inducible ETV2 activation.Angiogenesis · 2024Article
- Tertiary lymphoid structures: new immunotherapy biomarker.Frontiers in immunology · 2024Review
- Tertiary lymphoid structures in ovarian cancer.Frontiers in immunology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Bioengineering strategies for the fabrication of implantable lymphoid structures mimicking lymph nodes (LNs) and tertiary lymphoid structures (TLS) could amplify the adaptive immune response for therapeutic applications such as cancer immunotherapy. No method to date has resulted in the consistent formation of high endothelial venules (HEVs), which is the specialized vasculature responsible for naïve T cell recruitment and education in both LNs and TLS. Here orthogonal induced differentiation of human pluripotent stem cells carrying a regulatable ETV2 allele is used to rapidly and efficiently induce endothelial differentiation. Assembly of embryoid bodies combining primitive inducible endothelial cells and primary human LN fibroblastic reticular cells results in the formation of HEV-like structures that can aggregate into 3D organoids (HEVOs). Upon transplantation into immunodeficient mice, HEVOs successfully engraft and form lymphatic structures that recruit both antigen-presenting cells and adoptively-transferred lymphocytes, therefore displaying basic TLS capabilities. The results further show that functionally, HEVOs can organize an immune response and promote anti-tumor activity by adoptively-transferred T lymphocytes. Collectively, the experimental approaches represent an innovative and scalable proof-of-concept strategy for the fabrication of bioengineered TLS that can be deployed in vivo to enhance adaptive immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.